ArticleIranian journal of microbiology2020
The high efficacy of luliconazole against environmental and otomycosis
Article in Iranian journal of microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 10 citations in OpenAlex.
- The efficacy of luliconazole and caspofungin on planktonic and biofilm ofIranian journal of microbiology · 2025Article
- Prevalence of fungi and their antifungal and disinfectant resistance in hospital environments: insights into combating nosocomial mycoses.Antimicrobial resistance and infection control · 2025Article
- Mycoviruses in Fungi: Carcinogenesis of Fungal Agents May Not Always Be Mycotoxin Related.Journal of fungi (Basel, Switzerland) · 2023Article
- Multicenter Study of Susceptibility of Aspergillus Species Isolated from Iranian University Hospitals to Seven Antifungal Agents.Microbiology spectrum · 2022Article
- Evaluation of catalase activity of clinical and environmental isolates ofIranian journal of microbiology · 2022Article
- Genotypic diversity of Iranian Cryptococcus neoformans using multilocus sequence typing (MLST) and susceptibility to antifungals.Molecular biology reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesLuliconazole is currently confirmed for the topical therapy of dermatophytosis. Moreover, it is found that luliconazole has MATERIALS AND
methodsThirty eight isolates of
resultsLuliconazole with extremely low MIC range, 0.00049-0.00781 μg/mL and MIC
conclusionThe analysis of our data clearly indicated that luliconazole (with MIC
Indexed as
Identifiers
32494352PMC7244823W3015272329What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.